DR-462 Defining a Pan-Cancer Heterochromatin Instability Signature
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-462 Defining a Pan-Cancer Heterochromatin Instability Signature
This project aims to define a computational framework to identify gene expression signatures that reflect heterochromatin instability across multiple cancer …
DR-338 Systematic discovery and characterization of cancer-specific expression patterns
Cancer is driven by genetic changes, and multiple genes that have oncogenic and tumor suppressive potential have been widely investigated. …
DR-449 SOSCLC-AECC: Advancing Precision Oncology in Small Cell Lung Cancer and Related Neuroendocrine Lung Cancers through Multi-OMICs Profiling
This project, as part of the SOSCLC-AECC Consortium, represents the largest initiative to date in Spain focused on understanding the …
DR-46- Identifying the mutational burden of tumor specific regulatory elements (REs) in breast cancer
Gene regulation is controlled by regulatory elements (REs) which are present in the non-coding regions of the genome. Accessibility of …
DR-455 Identifying novel targets for cancer treatment
We aim to identify novel targets for cancer treatment. (1) We will assess whether biomarkers for immunotherapy outcome in melanoma, …
DR-448 Determinants of treatment-induced mutagenesis in cancer
Platinum drugs, including the most frequently used cisplatin, cause mutations in the genome, thereby contributing to the evolution of resistance …
DR-437 Multi-omics small intestinal neuroendocrine tumors
We aim to gain a deeper understanding of the pathophysiology of small intestinal neuroendocrine tumors, with a particular focus on …
DR-451 Clinical-driven discovery of noncoding cancer drivers and related transcriptomic and prognostic features
Cancer cells accumulate genetic mutations, with only a few required to trigger malignancy. Previous research has focused on coding mutations, …
DR-450 Identifying mechanisms for the ubiquitous differential gene expressions in homologous recombination deficient tumours
This project investigates why tumors with homologous recombination deficiency (HRD), a specific type of impaired DNA damage repair, show widespread changes in …
DR-445 Predicting and evaluating resistance to CDK4/6 therapies in metastatic Breast Cancer Patients
This project aims to predict the response of luminal metastatic breast cancer patients to standard of care treatment, helping to …
DR-440 Artificial Intelligence (AI) Foundation Model for Learning Novel Treatment Response Mechanisms in Large International Pan-Cancer Datasets to Improve Triple-Negative-Breast-Cancer (TNBC) Outcomes
This project uses artificial intelligence (AI) to analyze large amounts of data from cancer patients across different types of cancer, …
DR-438 Characterizing ABCB1 fusions in drug-resistant cancers
ABCB1 encodes a protein that causes chemotherapy resistance. We aim to determine what causes ABCB1 expression in drug-resistant cancers. This …
Kanker ontstaat door mutaties in het DNA. Er zijn steeds meer geneesmiddelen die werkzaam zijn bij specifieke fouten in het DNA van de tumor van een individuele patiënt. Een medicijn dat niet past als een sleutel in het slot werkt niet, terwijl je wel het risico van de bijwerkingen hebt.